Lithuania vs Niger: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Lithuania
87.0%
in 2025
Niger
87.0%
in 2025
Lithuania rank
86th
Niger rank
86th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Lithuania
- Niger
How they compare
Lithuania currently reports 87.0% against 87.0% in Niger, a difference of 0.0%.
The two have swapped places 6 times across 18 shared years of data; in 2008 it was Niger ahead.
Lithuania ranks 86th and Niger ranks 86th of 194 countries.
Niger has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Lithuania | Niger | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 32.9% | 38.3% | 5.4% | Niger |
| 2020s | 83.7% | 84.2% | 0.5% | Niger |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Lithuania or Niger?
- Lithuania, at 87.0% against 87.0% in Niger as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Lithuania and Niger?
- 0.0%, with Lithuania ahead.
- How many years of comparable data are there for Lithuania and Niger?
- 18 years are reported by both, from 2008 to 2025.
- How do Lithuania and Niger rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Lithuania ranks 86th and Niger ranks 86th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.